A biodegradable filament for controlled drug delivery

Journal of Controlled Release

Volumn 139, Issue 3, 2009, Pages 205-211

  Mack, Brendan C ^a   Wright, Kenneth W ^b   Davis, Mark E ^a  

^a California Institute of Technology   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Drug containing filament; Mechanical properties; Ophthalmic; Poly(lactide co glycolide); Wet spinning

Indexed keywords

COAGULATION BATH; COMPOSITIONAL ANALYSIS; CONTROLLED DELIVERY; DEXAMETHASONES; DRUG CONTAINING FILAMENT; DRUG LOADING; DRUG RELEASE KINETICS; DRUG RETENTION; IN-VITRO; IN-VIVO; INDEPENDENT MEASUREMENT; LEVOFLOXACIN; MECHANICAL PROPERTIES TESTING; NEW ZEALAND WHITE RABBIT; OPHTHALMIC; POLY(LACTIDE-CO-GLYCOLIDE); RABBIT EYES; THERMAL AND MECHANICAL PROPERTIES; TIME DEPENDENT; TIME TO FAILURE; WET-SPINNING;

COAGULATION; DIMETHYL SULFOXIDE; DISSOLUTION; DRUG PRODUCTS; FILAMENTS (LAMP); MECHANICAL PROPERTIES; POLYMER BLENDS;

CONTROLLED DRUG DELIVERY;

DEXAMETHASONE; DIMETHYL SULFOXIDE; LEVOFLOXACIN; POLYGLACTIN;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABILITY; CHEMICAL COMPOSITION; CONJUNCTIVA; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG IMPLANT; DRUG RELEASE; DRUG TOLERABILITY; GLASS TRANSITION TEMPERATURE; LACRIMAL FLUID LEVEL; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RABBIT; THERMODYNAMICS;

ABSORBABLE IMPLANTS; ADMINISTRATION, TOPICAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CONJUNCTIVA; DELAYED-ACTION PREPARATIONS; DEXAMETHASONE; DIMETHYL SULFOXIDE; DRUG CARRIERS; DRUG COMPOUNDING; LACTIC ACID; OFLOXACIN; POLYGLYCOLIC ACID; RABBITS; SOLUBILITY; SOLVENTS; SURFACE PROPERTIES; TEARS; TENSILE STRENGTH; TRANSITION TEMPERATURE;

EID: 70349338799     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.06.020     Document Type: Article

References (37)

1. Holland G.N., and Stiehm E.R. Special considerations in the evaluation and management of uveitis in children. Am. J. Ophthalmol. 135 6 (2003) 867-878
2. Jampel H.D., Schwartz G.F., Robin A.L., Abrams D.A., Johnson E., and Miller R.B. Patient preferences for eye drop characteristics a willingness-to-pay analysis. Arch. Ophthalmol. 121 (2003) 540-546
3. Winfield A.J., Jessiman D., Williams A., and Esakowitz L. A study of the causes of non-compliance by patients prescribed eyedrops. Br. J. Ophthalmol. 74 8 (1990) 477-480
4. Kaur I.P., and Smitha R. Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery. Drug Dev. Ind. Pharm. 28 4 (2002) 353-369
5. Le Bourlais C., Acar L., Zia H., Sado P.A., Needham T., and Leverge R. Ophthalmic drug delivery systems - recent advances. Prog. Retin. Eye Res. 17 1 (1998) 33-58
6. Robert P.Y., and Adenis J.P. Comparative review of topical ophthalmic antibacterial preparations. Drugs 61 2 (2001) 175-185
7. Kato A., Kimura H., Okabe K., Okabe J., Kunou N., and Ogura Y. Feasibility of drug delivery to the posterior pole of the rabbit eye with an episderal implant. Invest. Ophthalmol. Vis. Sci. 45 1 (2004) 238-244
8. Chiang C.H., Tung S.M., Lu D.W., and Yeh M.K. In vitro and in vivo evaluation of an ocular delivery system of 5-fluorouracil microspheres. J. Ocul. Pharmacol. Ther. 17 6 (2001) 545-553
9. Saishin Y., Silva R.L., Callahan K., Schoch C., Ahlheim M., Lai H., Kane F., Brazzell R.K., Bodmer D., and Campochiaro P.A. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest. Ophthalmol. Vis. Sci. 44 11 (2003) 4989-4993
10. Choy Y.B., Park J.H., McCarey B.E., Edelhauser H.F., and Prausnitz M.R. Mucoadhesive microdiscs engineered for ophthalmic drug delivery: effect of particle geometry and formulation on preocular residence time. Invest. Ophthalmol. Vis. Sci. 49 11 (2008) 4808-4815
11. Ceulemans J., Vermeire A., Adriaens E., Remon J.P., and Ludwig A. Evaluation of a mucoadhesive tablet for ocular use. J. Control. Release 77 3 (2001) 333-344
12. Tan D.T., Chee S.P., Lim L., and Lim A.S. Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 106 2 (1999) 223-231
13. Weyenberg W., Vermeire A., Dhondt M.M.M., Adriaens E., Kestelyn P., Remon J.P., and Ludwig A. Ocular bioerodible minitablets as strategy for the management of microbial keratitis. Invest. Ophthalmol. Vis. Sci. 45 9 (2004) 3229-3233
14. Weyenberg W., Vermeire A., Remon J.P., and Ludwig A. Characterization and in vivo evaluation of ocular bioadhesive minitablets compressed at different forces. J. Control. Release 89 2 (2003) 329-340
15. Theng J.T.S., Ei T.S., Zhou L., Lam K.W., Chee S.P., and Tan D. Pharmacokinetic and toxicity study of an intraocular cyclosporine DDS in the anterior segment of rabbit eyes. Invest. Ophthalmol. Vis. Sci. 44 11 (2003) 4895-4899
16. Kuppermann B.D., Blumenkranz M.S., Haller J.A., Williams G.A., Weinberg D.V., Chou C., and Whitcup S.M. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. 125 3 (2007) 309-317
17. Silva-Cunha A., Fialho S., Naud M.C., and Behar-Cohen F. Poly-ε-caprolactone intravitreous devices: an in vivo study. Invest. Ophthalmol. Vis. Sci. 50 (2008) 2312-2318
18. Pijls R.T., Sonderkamp T., Daube G.W., Krebber R., Hanssen H.H.L., Nuijts R., and Koole L.H. Studies on a new device for drug delivery to the eye. Eur. J. Pharm. Biopharm. 59 2 (2005) 283-288
19. Zhou T., Lewis H., Foster R.E., and Schwendeman S.P. Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy. J. Control. Release 55 2-3 (1998) 281-295
20. Kohn J., Abramson S., and Langer R. Biodegradable and bioerodible materials. In: Ratner B., Hoffman A., Schoen F., and Lemons J. (Eds). Biomaterials Science. Second Edition (2004), Elsevier Academic Press, San Diego, CA 115-127
21. Langer R. Biomaterials and biomedical engineering. Chem. Eng. Sci. 50 24 (1995) 4109-4121
22. Alexis F. Factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly (lactic acid)-co-(glycolic acid). Polymer Int. 54 1 (2005) 36-46
23. Siepmann J., and Göpferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv. Drug Del. Rev. 48 2-3 (2001) 229-247
24. Crow B.B., Borneman A.F., Hawkins D.L., Smith G.M., and Nelson K.D. Evaluation of in vitro drug release, pH change, and molecular weight degradation of poly (l-lactic acid) and poly (d, l-lactide-co-glycolide) fibers. Tissue Eng. 11 7/8 (2005) 1077-1084
25. Crow B.B., and Nelson K.D. Release of bovine serum albumin from a hydrogel-cored biodegradable polymer fiber. Biopolymers 81 6 (2006) 419-427
26. Gao H., Gu Y., and Ping Q. The implantable 5-fluorouracil-loaded poly (l-lactic acid) fibers prepared by wet-spinning from suspension. J. Control. Release 118 3 (2007) 325-332
27. Zilberman M., Nelson K.D., and Eberhart R.C. Mechanical properties and in vitro degradation of bioresorbable fibers and expandable fiber-based stents. J. Biomed. Mater. Res. Part B: Appl. Biomater. 74 (2005) 792-799
28. Nelson K.D., Romero A., Waggoner P., Crow B., Borneman A., and Smith G.M. Technique paper for wet-spinning poly(l-lactic acid) and poly(dl-lactide-co-glycolide) monofilament fibers. Tissue Eng. 9 6 (2003) 1323-1330
29. Davis R., and Bryson M. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47 4 (1994) 677-700
30. Aderriotis D., and Sandor G.K.B. Outcomes of irradiated polyglactin 910 vicryl rapide fast-absorbing suture in oral and scalp wounds. J. Can. Dent. Assoc. 65 6 (1999) 345-347
31. Cleland J.L., Duenas E., Daugherty A., Marian M., Yang J., Wilson M., Celniker A.C., Shahzamani A., Quarmby V., and Chu H. Recombinant human growth hormone poly (lactic-co-glycolic acid)(PLGA) microspheres provide a long lasting effect. J. Control. Release 49 2-3 (1997) 193-205
32. Giordano G.G., Refojo M.F., and Arroyo M.H. Sustained delivery of retinoic acid from microspheres of biodegradable polymer in PVR. Invest. Ophthalmol. Vis. Sci. 34 9 (1993) 2743-2751
33. Jones K.S. Effects of biomaterial-induced inflammation on fibrosis and rejection. Semin. Immunol. 20 2 (2008) 130-136
34. Zeng J., Yang L., Liang Q., Zhang X., Guan H., Xu X., Chen X., and Jing X. Influence of the drug compatibility with polymer solution on the release kinetics of electrospun fiber formulation. J. Control. Release 105 1-2 (2005) 43-51
35. Ma D., and McHugh A.J. The interplay of phase inversion and membrane formation in the drug release characteristics of a membrane-based delivery system. J. Mem. Sci. 298 1-2 (2007) 156-168
36. Baltch A.L., Smith R.P., and Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob. Agents Chemother. 39 8 (1995) 1661-1666
37. Sihvola P., and Puustjarvi T. Practical problems in the use of Ocusert-pilocarpine delivery system. Acta Ophthalmol. Scand. Suppl. 58 6 (1980) 933-937